Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Trial Profile

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Phase of Trial: Phase II

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Influenza virus vaccine (NasoVAX) (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Proof of concept
  • Sponsors Altimmune
  • Most Recent Events

    • 28 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 07 Oct 2018 Results presented at the IDWeek 2018
    • 04 Sep 2018 According to an Altimmune media release, the company will present the full data-set at IDWeek, an international infectious disease conference in October 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top